Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?

Company Performance - Adverum Biotechnologies (ADVM) has returned 50.6% year-to-date, significantly outperforming the Medical sector's average return of 0.3% [2] - The Zacks Consensus Estimate for ADVM's full-year earnings has increased by 40.7% over the past quarter, indicating stronger analyst sentiment and an improving earnings outlook [2] - Adverum Biotechnologies holds a Zacks Rank of 2 (Buy), suggesting a favorable investment outlook [1][2] Industry Context - Adverum Biotechnologies is part of the Medical - Biomedical and Genetics industry, which consists of 506 stocks and currently ranks 77 in the Zacks Industry Rank [3] - The average performance of stocks in the Medical - Biomedical and Genetics industry has declined by 8.8% this year, highlighting Adverum's superior performance [3] - In comparison, Aurora Cannabis Inc., which operates in the Medical - Products industry ranked 149, has a year-to-date return of 31.9% and a consensus EPS estimate increase of 46.7% over the past three months [2][3]